PDCD1 and cancer: While the PD-1/PD-L1 pathway (pembrolizumab, nivolumab/avelumab, atezolumab) has been extensively studied in cancer, including ovarian, the role of PD-L2 in cancer and immunity is less clear and the therapeutic role for PD-L2 inhibition has not been broadly explored.